Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
8.30
Dollar change
+0.14
Percentage change
1.72
%
IndexRUT P/E- EPS (ttm)-2.79 Insider Own29.71% Shs Outstand127.46M Perf Week3.62%
Market Cap1.09B Forward P/E- EPS next Y-2.83 Insider Trans-0.05% Shs Float92.20M Perf Month-17.66%
Income-341.97M PEG- EPS next Q-0.74 Inst Own71.65% Short Float12.81% Perf Quarter-27.19%
Sales25.55M P/S42.61 EPS this Y-3.44% Inst Trans1.51% Short Ratio10.79 Perf Half Y0.48%
Book/sh5.90 P/B1.41 EPS next Y1.78% ROA-35.19% Short Interest11.81M Perf Year-44.67%
Cash/sh5.72 P/C1.45 EPS next 5Y- ROE-40.18% 52W Range5.95 - 19.23 Perf YTD-24.61%
Dividend Est.- P/FCF- EPS past 5Y-38.74% ROI-42.72% 52W High-56.84% Beta1.63
Dividend TTM- Quick Ratio25.44 Sales past 5Y319.82% Gross Margin79.38% 52W Low39.50% ATR (14)0.54
Dividend Ex-Date- Current Ratio25.44 EPS Y/Y TTM-7.58% Oper. Margin-1485.19% RSI (14)43.23 Volatility5.75% 6.01%
Employees323 Debt/Eq0.07 Sales Y/Y TTM1749.89% Profit Margin-1338.60% Recom1.33 Target Price23.05
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-19.95% Payout- Rel Volume0.62 Prev Close8.16
Sales Surprise-100.69% EPS Surprise6.71% Sales Q/Q-100.00% EarningsFeb 22 AMC Avg Volume1.09M Price8.30
SMA20-6.42% SMA50-11.97% SMA200-15.62% Trades Volume679,715 Change1.72%
Date Action Analyst Rating Change Price Target Change
Apr-20-23Upgrade Jefferies Underperform → Hold $12.50
Apr-19-23Upgrade Raymond James Outperform → Strong Buy $29
Apr-13-23Initiated Raymond James Outperform $29
Feb-03-23Initiated Oppenheimer Outperform $33
Sep-30-22Initiated Barclays Equal Weight $23
Sep-02-22Initiated Stifel Buy $40
Jun-06-22Initiated Jefferies Underperform $13
Feb-01-22Initiated Berenberg Buy $45
Jul-21-21Initiated BofA Securities Buy $50
Dec-15-20Reiterated H.C. Wainwright Buy $54 → $57
Mar-17-24 05:20PM
Mar-15-24 12:39PM
Mar-13-24 09:55AM
Feb-26-24 04:05PM
09:55AM
04:40PM Loading…
Feb-22-24 04:40PM
04:05PM
Feb-15-24 04:05PM
10:00AM
03:29AM
Feb-01-24 04:05PM
Jan-18-24 05:37AM
Jan-08-24 07:00AM
Jan-02-24 04:05PM
Nov-30-23 09:55AM
09:55AM Loading…
Nov-14-23 09:55AM
Nov-07-23 04:05PM
Nov-02-23 06:21PM
04:05PM
Oct-31-23 12:00PM
Oct-26-23 04:05PM
10:02AM
Oct-12-23 04:05PM
Sep-18-23 04:05PM
Aug-31-23 10:16PM
Aug-08-23 06:05PM
04:02PM
Aug-01-23 04:05PM
May-25-23 05:01PM
May-24-23 04:05PM
08:16AM Loading…
May-18-23 08:16AM
May-04-23 07:25PM
04:05PM
Apr-27-23 04:05PM
10:03AM
Apr-21-23 02:48PM
Apr-20-23 02:20AM
Apr-19-23 07:30AM
Apr-18-23 10:40AM
Apr-14-23 05:05AM
Apr-13-23 06:12PM
03:49PM
Apr-07-23 07:44AM
Apr-06-23 09:55AM
Mar-06-23 07:30AM
Mar-01-23 07:30AM
Feb-25-23 07:31AM
Feb-23-23 05:45PM
04:05PM
Feb-21-23 10:00AM
Feb-16-23 04:05PM
10:01AM
Feb-07-23 05:01PM
Feb-02-23 07:30AM
Jan-13-23 11:11AM
Jan-03-23 07:30AM
Dec-31-22 08:53AM
Nov-24-22 08:02AM
Nov-17-22 01:58PM
Nov-07-22 07:30AM
Nov-03-22 06:35PM
04:05PM
Oct-27-22 04:05PM
Oct-14-22 10:14AM
Sep-26-22 07:30AM
Sep-23-22 07:30AM
Sep-12-22 09:30PM
07:00AM
06:30AM
Sep-11-22 09:45AM
Sep-08-22 04:06PM
10:25AM
Aug-30-22 11:15AM
Aug-25-22 02:48PM
Aug-18-22 04:05PM
Aug-04-22 04:05PM
Jul-28-22 04:05PM
Jun-27-22 06:00AM
Jun-16-22 07:30AM
May-26-22 07:30AM
May-07-22 09:59AM
May-05-22 04:05PM
May-03-22 07:30AM
Apr-28-22 04:05PM
Feb-24-22 04:05PM
Feb-17-22 04:05PM
Feb-10-22 11:51AM
Feb-02-22 07:30AM
Jan-04-22 07:30AM
Jan-03-22 07:30AM
Dec-22-21 11:11AM
Dec-18-21 12:38AM
Dec-10-21 07:30AM
Nov-17-21 11:39AM
Nov-16-21 12:36PM
Nov-10-21 04:05PM
Nov-04-21 04:05PM
08:14AM
Oct-27-21 01:23PM
04:50AM
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bergstrom Donald APresident, R&DJan 29 '24Sale9.643,17830,636530,878Jan 31 04:08 PM
Catinazzo ThomasChief Financial OfficerJan 29 '24Sale9.642,00519,328341,846Jan 31 04:11 PM
Adams BrianChief Legal OfficerJan 29 '24Sale9.641,92918,596327,738Jan 31 04:05 PM
Rahmer PeterSee remarksJan 29 '24Sale9.641,65115,916514,977Jan 31 04:14 PM
Bergstrom Donald APresident, R&DDec 27 '23Sale11.5197711,245234,056Dec 29 04:17 PM
Catinazzo ThomasChief Financial OfficerDec 27 '23Sale11.512943,384143,851Dec 29 04:22 PM
Adams BrianChief Legal OfficerDec 27 '23Sale11.512943,384129,667Dec 29 04:14 PM
Rahmer PeterSee remarksDec 27 '23Sale11.512442,808316,628Dec 29 04:26 PM
Bergstrom Donald APresident, R&DOct 30 '23Sale6.033,45120,810235,033Nov 01 04:14 PM
Catinazzo ThomasChief Financial OfficerOct 30 '23Sale6.031,69710,233144,145Nov 01 04:18 PM
Adams BrianChief Legal OfficerOct 30 '23Sale6.031,6329,841129,961Nov 01 04:07 PM
Rahmer PeterSee remarksOct 30 '23Sale6.031,3548,165316,872Nov 01 04:21 PM
Bergstrom Donald APresident, R&DSep 27 '23Sale8.386485,430238,484Sep 29 04:52 PM
Catinazzo ThomasChief Financial OfficerSep 27 '23Sale8.382942,464145,842Sep 29 04:22 PM
Adams BrianChief Legal OfficerSep 27 '23Sale8.382942,464131,593Sep 29 04:10 PM
Rahmer PeterSee remarksSep 27 '23Sale8.382442,045318,226Sep 29 04:32 PM
Bergstrom Donald APresident, R&DJul 28 '23Sale11.802,68331,659237,904Jul 31 04:48 PM
Catinazzo ThomasChief Financial OfficerJul 28 '23Sale11.801,69319,977146,136Jul 31 04:50 PM
Adams BrianChief Legal OfficerJul 28 '23Sale11.801,62819,210131,887Jul 31 04:46 PM
Rahmer PeterSee remarksJul 28 '23Sale11.801,35215,954316,808Jul 31 04:52 PM
Bergstrom Donald APresident, R&DJun 27 '23Sale12.126477,842240,587Jun 28 05:06 PM
Adams BrianChief Legal OfficerJun 27 '23Sale12.122943,563133,515Jun 28 05:02 PM
Catinazzo ThomasChief Financial OfficerJun 27 '23Sale12.122943,563147,829Jun 28 05:08 PM
Rahmer PeterSee remarksJun 27 '23Sale12.122442,957318,160Jun 28 05:12 PM
Bergstrom Donald APresident, R&DApr 28 '23Sale11.161,38315,434242,701May 01 04:29 PM
Adams BrianChief Legal OfficerApr 28 '23Sale11.168639,631134,882May 01 04:26 PM
Catinazzo ThomasChief Financial OfficerApr 28 '23Sale11.168639,631149,272May 01 04:31 PM
Rahmer PeterSee remarksApr 28 '23Sale11.167398,247157,504May 01 04:33 PM
Last Close
Mar 28 04:00PM ET
129.46
Dollar change
-0.77
Percentage change
-0.59
%
SRPT Sarepta Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-6.16 Insider Own5.98% Shs Outstand93.73M Perf Week3.62%
Market Cap12.15B Forward P/E11.45 EPS next Y11.31 Insider Trans0.92% Shs Float88.24M Perf Month-5.85%
Income-535.98M PEG- EPS next Q-0.03 Inst Own86.85% Short Float5.63% Perf Quarter33.68%
Sales1.24B P/S9.77 EPS this Y143.14% Inst Trans6.40% Short Ratio4.61 Perf Half Y4.88%
Book/sh9.17 P/B14.12 EPS next Y351.90% ROA-16.77% Short Interest4.97M Perf Year-1.28%
Cash/sh17.86 P/C7.25 EPS next 5Y- ROE-86.15% 52W Range55.25 - 159.89 Perf YTD34.25%
Dividend Est.- P/FCF- EPS past 5Y-1.21% ROI-25.13% 52W High-19.03% Beta0.94
Dividend TTM- Quick Ratio3.45 Sales past 5Y32.89% Gross Margin84.34% 52W Low134.32% ATR (14)3.77
Dividend Ex-Date- Current Ratio3.95 EPS Y/Y TTM24.04% Oper. Margin-21.54% RSI (14)57.99 Volatility2.32% 3.16%
Employees1314 Debt/Eq1.63 Sales Y/Y TTM33.26% Profit Margin-43.11% Recom1.43 Target Price164.33
Option/ShortYes / Yes LT Debt/Eq1.48 EPS Q/Q134.77% Payout- Rel Volume0.73 Prev Close130.23
Sales Surprise2.48% EPS Surprise582.15% Sales Q/Q53.54% EarningsFeb 28 AMC Avg Volume1.08M Price129.46
SMA203.81% SMA503.21% SMA20016.58% Trades Volume786,422 Change-0.59%
Date Action Analyst Rating Change Price Target Change
Jan-31-24Initiated BMO Capital Markets Outperform $170
Dec-13-23Resumed Citigroup Buy $113
Dec-12-23Initiated Deutsche Bank Buy $109
Nov-21-23Initiated Wedbush Outperform $224
Oct-31-23Downgrade Oppenheimer Outperform → Perform
Oct-31-23Downgrade Cantor Fitzgerald Overweight → Neutral $166 → $40
Jun-23-23Downgrade Evercore ISI Outperform → In-line $139
Apr-26-23Initiated SMBC Nikko Outperform $185
Apr-04-23Initiated Citigroup Buy $179
Mar-01-23Upgrade Morgan Stanley Equal-Weight → Overweight $141 → $187
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
01:18AM Loading…
Mar-12-24 01:18AM
Mar-11-24 09:03AM
Mar-06-24 11:54PM
Mar-04-24 09:47AM
08:30AM
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM Loading…
12:00AM
Feb-28-24 06:00PM
04:23PM
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
08:30AM
Feb-20-24 10:00AM
Feb-19-24 03:26AM
Feb-16-24 11:23AM
11:22AM
08:46AM
07:41AM
07:22AM
07:00AM Loading…
07:00AM
Feb-15-24 07:45AM
Feb-11-24 01:45AM
Jan-31-24 06:29PM
Jan-29-24 07:37AM
07:12AM
07:00AM
06:50AM
Jan-26-24 05:15AM
Jan-25-24 09:45AM
Jan-22-24 05:47PM
09:55AM
09:38AM
Jan-16-24 03:57PM
09:02AM
Jan-10-24 11:43AM
06:17AM
Jan-09-24 11:22AM
10:52AM
07:15AM
Jan-08-24 11:55AM
Jan-04-24 09:55AM
Jan-02-24 08:30AM
Dec-29-23 06:27PM
08:44AM
Dec-28-23 10:07AM
Dec-27-23 06:26PM
Dec-26-23 06:56PM
Dec-22-23 02:49PM
10:15AM
08:00AM
06:33AM
Dec-17-23 09:45AM
Dec-15-23 09:55AM
Dec-12-23 12:43PM
Dec-09-23 07:00AM
Dec-01-23 11:31AM
Nov-30-23 06:34PM
Nov-29-23 09:55AM
Nov-27-23 09:50AM
Nov-24-23 10:26AM
Nov-18-23 06:49AM
Nov-16-23 06:35AM
Nov-13-23 09:55AM
07:57AM
Nov-10-23 12:58AM
Nov-09-23 10:00AM
Nov-08-23 10:15AM
Nov-07-23 11:23PM
Nov-02-23 06:25PM
12:18PM
08:30AM
12:00AM
Nov-01-23 05:03PM
04:29PM
04:05PM
Oct-31-23 07:02PM
04:19PM
04:07PM
03:03PM
11:52AM
10:26AM
10:21AM
09:38AM
09:19AM
08:01AM
07:51AM
07:19AM
Oct-30-23 04:28PM
04:10PM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boor Kathryn JeanDirectorMar 11 '24Sale122.9376193,5507,516Mar 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Option Exercise13.9015,000208,50037,840Mar 11 08:02 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Sale123.2515,0001,848,79522,840Mar 11 08:02 PM
Mayo StephenDirectorMar 05 '24Sale122.963,135385,4806,621Mar 06 08:00 PM
Arif BilalChief Tech Ops OfficerMar 01 '24Sale128.842,000257,67626,836Mar 05 08:00 PM
Brown Ryan EdwardEVP, General CounselMar 01 '24Sale125.342,000250,68031,827Mar 05 08:00 PM
Estepan Ian MichaelChief Financial OfficerMar 01 '24Sale128.301,200153,96039,114Mar 05 08:00 PM
BEHRENS M KATHLEENDirectorNov 03 '23Option Exercise29.0315,000435,450174,993Nov 06 08:00 AM
Barry RichardDirectorNov 03 '23Buy78.8150,0003,940,500140,000Nov 06 08:00 AM
INGRAM DOUGLAS SPresident & CEONov 03 '23Buy79.3625,2252,001,800390,307Nov 06 08:00 AM
Chambers Michael AndrewDirectorAug 14 '23Buy109.479,9791,092,429246,996Aug 15 08:00 AM
Chambers Michael AndrewDirectorAug 11 '23Buy108.0523,6862,559,272237,017Aug 14 08:00 AM
Chambers Michael AndrewDirectorAug 10 '23Buy106.1534,8673,701,067213,331Aug 11 07:40 AM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Option Exercise29.0315,000435,45035,994Aug 08 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Sale106.7215,0001,600,80020,994Aug 08 08:00 PM